Grace Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 23, 2025
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended March 31, 2025 | Year Ended March 31, 2024 | |
|---|---|---|
| (Expressed in thousands) | $ | $ |
| Cash flows from operating activities: | ||
| Net loss | (9,568) | (12,853) |
| Adjustments: | ||
| Depreciation expense | 7 | 11 |
| Gain on sale of equipment | — | (59) |
| Loss on disposal | 2 | 39 |
| Stock-based compensation | 730 | 913 |
| Change in fair value of derivative warrant liabilities | (3,218) | 2,728 |
| Deferred income tax benefit | (3,199) | (1,832) |
| Changes in operating assets and liabilities: | ||
| Receivables | 596 | 80 |
| Prepaid expenses | (170) | 315 |
| Trade and other payables | (84) | (1,652) |
| Operating lease right of use asset | — | (23) |
| Net cash used in operating activities | (14,904) | (12,333) |
| Cash flows from investing activities: | ||
| Maturity of short-term investments | 15 | 6,569 |
| Purchase of short-term investments | (15) | (6,554) |
| Purchase of equipment | — | (22) |
| Sale of equipment | — | 111 |
| Net cash provided by investing activities | — | 104 |
| Cash flows from financing activities: | ||
| Gross proceeds from issuance of common stock and warrants from private placement | 14,999 | 7,500 |
| Stock issuance costs | (967) | (162) |
| Proceeds from issuance of common stock from exercise of stock options | — | 21 |
| Net cash provided by financing activities | 14,032 | 7,359 |
| Net decrease in cash and cash equivalents | (872) | (4,870) |
| Cash and cash equivalents, beginning of year | 23,005 | 27,875 |
| Cash and cash equivalents, end of year | 22,133 | 23,005 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 830 | 3,280 |
| Cash equivalents | 21,303 | 19,725 |
| Supplemental schedule of non-cash financing activities are comprised of: | ||
| Issuance costs in accounts payable | 327 | — |
(Formerly ACASTI PHARMA, INC.)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.